Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

Why is Target's CEO stepping down? How will tariffs impact U.S. retailers? What caused Nvidia stock to drop recently? Why did Meta freeze AI hiring? How will US stake in Intel affect chip industry? What’s behind Walmart’s frozen shrimp recall? Why is Google leading in AI smartphone race?

Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

benzinga.com/news/health-care/25/08/47207867/like-eli-lilly-viking-therapeutics-oral-weight-loss-drug-disappoints-stock-tanks

On Tuesday, Viking Therapeutics Inc. (NASDAQ:VKTX) released the much-awaited data from its Phase 2 trial of VK2735 pill, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
VK2735 is being developed in oral…

This story appeared on benzinga.com, 2025-08-19 13:28:28.